Mutations in BRAF, the downstream effector of KRAS are reported in up to 70% of melanoma cancer cell lines [27] and they are highly prevalent in most common cancers with poor prognosis such as malignant melanoma [27, 28, 180] (Figures 4–5). The gene discussed is KRAS; the disease is cancer.